Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell... Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
- Mechanism
- Curator reviewed · 5 references
Ensartinib inhibits the anaplastic lymphoma kinase (ALK) protein and most of its alternations which includes fusions and mutants. It also potently inhibits the ephrin type-A receptor 2 (EphA2) protein. Ensartinib is also an inhibitor of the MET and ROS1 kinases.
- Primary indication
- Ensartinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced non-small cell lung cancer (NSCLC) or adult patients with metastatic NSCLC who have also previously not received an ALK-inhibitor.Curator reviewed · 2 structured indications
- Formula / weight
- C26H27Cl2FN6O3 · 561.44 g/mol (avg)
- First approval
- United States, 2025
- Code names
- X-396
- Brand names
Resolves to
GLYMPHUVMRFTFV-QLFBSQMISA-NSMILESC[C@@H](OC1=CC(=NN=C1N)C(=O)NC1=CC=C(C=C1)C(=O)N1C[C@H](C)N[C@H](C)C1)C1=C(Cl)C=CC(F)=C1ClWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Ensartinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account